

New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer

We are excited to announce that our recent study on different clinical applications of the TK 210 ELISA in ovarian cancer has been accepted for publication in the Karger Oncology journal. The study focused on demonstrating the clinical utility of TK1-specific activity (TK1 SA) in the early detection of ovarian cancer.

This study was conducted in collaboration with Professor Josko Osredkar and is titled "Clinical Significance of the TK1 specific Activity in the Early Detection of Ovarian Cancer". TK1 SA is determined by calculating the ratio of TK1 activity by TK-Liaison and TK1 protein by AroCell TK 210 ELISA. The study included 134 patients with ovarian tumors (72 benign and 62 malignant) and 64 healthy age-matched controls.

The study results revealed that TK1 SA, which complements traditional biomarkers such as CA 125 and HE4, significantly improved the sensitivity for early detection of benign and malignant ovarian cancer. The combination of various biomarkers provided a more comprehensive and accurate diagnostic approach. These findings have implications in proving the early detection rates and subsequent treatment outcomes for ovarian cancer patients.

Furthermore, the study observed the fluctuations in TK1 SA levels in relation to surgery and chemotherapy which provided valuable information for monitoring the effectiveness of treatment and assessing disease progression.

"We are delighted by the acceptance of our study in the Karger Oncology journal, and this will further widen the clinical applications of TK 210 ELISA," said Kiran Kumar Jagarlamudi, co-author and CSO at AroCell. "This research highlights the potential of TK1 SA as an additional tool in the early detection of ovarian cancer.

According to WHO, ovarian cancer is the eighth most common cause of cancer and cancer death in women. A major concern is that almost two-thirds of cases are typically diagnosed in the late stage as the symptoms are unspecific in the early stage of ovarian cancer.

For more information on the study, visit [Karger Oncology journal](#).

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About TK 210 ELISA

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

[New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer](#)